Sanofi halts Phase 3 trial of Kevzara as a COVID-19 treatment
pharmafile | September 1, 2020 | News story | Manufacturing and Production | COVID-19, Sanofi, Vaccine, pharma
Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after data on its efficacy proved inconclusive.
The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Overall, it did not help those with less severe cases of the virus and in some cases the trial environment led to COVID-19 pneumonia infections and even death in a few instances.
John Reed, Sanofi’s Global Head of Research and Development, said: “Although this trial did not yield the results we hoped for, we are proud of the work that was achieved by the team to further our understanding of the potential use of Kevzara for the treatment of COVID-19. At Sanofi, we are committed to help combat the global COVID-19 pandemic, including developing vaccine candidates that can be manufactured at large scale.”
Kevzara is an injectable prescription drug that is an interleukin (Il-6) receptor blocker, and the treatment is primarily used for treating adult patients with moderately to severely active rheumatoid arthritis. The drug can lower a patient’s ability to fight infections which has led to deaths from people catching fungal infections or other serious illnesses like tuberculosis.
Sanofi is currently working on two coronavirus vaccines, and one is set to start clinical trials this month. So far, the US and Britain have secured deals for the vaccine candidates, with the EU set to agree its own deal in the coming weeks.
Conor Kavanagh
Related Content
Canada awards CSL Seqirus with influenza pandemic vaccine contract
CSL Seqirus has been awarded a contract committing it to manufacturing and delivering influenza vaccines …
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
